As shared on GlobeNewswire, a biotechnology company called ABLi Therapeutics has released encouraging findings from a research study on a potential new Parkinson’s treatment called risvodetinib. Here’s what you need to know in straightforward terms. What They Studied Researchers analyzed blood and spinal fluid samples from up to 80 people with early-stage, untreated Parkinson’s disease. […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.